Zilurgisertib pharmacokinetics support once-daily dosing, and renal clearance is not the predominant elimination route; zilurgisertib can be administered with or without food.

Strong correlations between plasma and saliva pharmacokinetics support the use of saliva pharmacokinetics as a surrogate for plasma pharmacokinetics, which would be beneficial for patients for whom blood draws are difficult, such as those with fibrodysplasia ossificans progressiva (FOP).

These pharmacokinetic and safety data support further clinical development of zilurgisertib, which is being studied for the treatment of patients with FOP and those with anemia of chronic disease.